Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Bershteyn

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Pathogens and Disease|July 10, 2018
Implementation and applications of EMOD, an individual-based multi-disease modeling platformAnna Bershteyn, Jaline Gerardin, Daniel Bridenbecker, et al.
The Lancet. Global Health|September 20, 2025
Effects of reductions in US foreign assistance on HIV, tuberculosis, family planning, and maternal and child health: a modelling studyJohn Stover, Emily Sonneveldt, Yvonne Tam, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 13, 2022
Self-Assessed Severity as a Determinant of Coronavirus Disease 2019 Symptom Specificity: A Longitudinal Cohort StudyAnna Bershteyn, Angela M Dahl, Tracy Q Dong, et al.
Eclinicalmedicine|March 8, 2021
Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trialChristine Johnston, Elizabeth R Brown, Jenell Stewart, et al.
Annals of Internal Medicine|December 7, 2020
Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized TrialRuanne V Barnabas, Elizabeth R Brown, Anna Bershteyn, et al.
The Lancet. HIV|January 15, 2023
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling studyJennifer Smith, Loveleen Bansi-Matharu, Valentina Cambiano, et al.
The Lancet. HIV|April 30, 2022
Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling studyAndrew N Phillips, Anna Bershteyn, Paul Revill, et al.
Nature|December 4, 2015
Sustainable HIV treatment in Africa through viral-load-informed differentiated care, Andrew Phillips, Amir Shroufi, et al.
The Lancet. Global Health|August 9, 2014
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical modelsJeffrey W Eaton, Nicolas A Menzies, John Stover, et al.
The Lancet. Global Health|August 2, 2014
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical modelsJeffrey W Eaton, Nicolas A Menzies, John Stover, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Pathogens and Disease|July 10, 2018
Implementation and applications of EMOD, an individual-based multi-disease modeling platformAnna Bershteyn, Jaline Gerardin, Daniel Bridenbecker, et al.
The Lancet. Global Health|September 20, 2025
Effects of reductions in US foreign assistance on HIV, tuberculosis, family planning, and maternal and child health: a modelling studyJohn Stover, Emily Sonneveldt, Yvonne Tam, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 13, 2022
Self-Assessed Severity as a Determinant of Coronavirus Disease 2019 Symptom Specificity: A Longitudinal Cohort StudyAnna Bershteyn, Angela M Dahl, Tracy Q Dong, et al.
Eclinicalmedicine|March 8, 2021
Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trialChristine Johnston, Elizabeth R Brown, Jenell Stewart, et al.
Annals of Internal Medicine|December 7, 2020
Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized TrialRuanne V Barnabas, Elizabeth R Brown, Anna Bershteyn, et al.
The Lancet. HIV|January 15, 2023
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling studyJennifer Smith, Loveleen Bansi-Matharu, Valentina Cambiano, et al.
The Lancet. HIV|April 30, 2022
Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling studyAndrew N Phillips, Anna Bershteyn, Paul Revill, et al.
Nature|December 4, 2015
Sustainable HIV treatment in Africa through viral-load-informed differentiated care, Andrew Phillips, Amir Shroufi, et al.
The Lancet. Global Health|August 9, 2014
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical modelsJeffrey W Eaton, Nicolas A Menzies, John Stover, et al.
The Lancet. Global Health|August 2, 2014
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical modelsJeffrey W Eaton, Nicolas A Menzies, John Stover, et al.
Pageof 10